Affimed (AFMD) to Release Earnings on Thursday

Affimed (NASDAQ:AFMD) is expected to announce its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.91) per share and revenue of $0.14 million for the quarter.

Affimed Stock Performance

AFMD stock opened at $0.87 on Tuesday. The stock has a fifty day moving average of $1.01 and a 200-day moving average of $2.17. Affimed has a fifty-two week low of $0.85 and a fifty-two week high of $8.95. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on AFMD. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Affimed in a research report on Tuesday, December 10th. Wells Fargo & Company dropped their price target on shares of Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $13.50.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.